Literature DB >> 22857808

Impact of chronic kidney disease on outcomes after abdominal aortic aneurysm repair.

Virendra I Patel1, Robert T Lancaster, Shankha Mukhopadhyay, Nathan J Aranson, Mark F Conrad, Glenn M LaMuraglia, Christopher J Kwolek, Richard P Cambria.   

Abstract

OBJECTIVE: Chronic kidney disease (CKD) is associated with increased morbidity and death after open abdominal aortic aneurysm (AAA) repair (OAR). This study highlights the effect of CKD on outcomes after endovascular AAA (EVAR) and OAR in contemporary practice.
METHODS: The National Surgical Quality Improvement Program (NSQIP) Participant Use File (2005-2008) was queried by Current Procedural Terminology (American Medical Association, Chicago, Ill) code to identify EVAR or OAR patients, who were grouped by CKD class as having mild (CKD class 1 or 2), moderate (CKD class 3), or severe (CKD class 4 or 5) renal disease. Propensity score analysis was performed to match OAR and EVAR patients with mild CKD with those with moderate or severe CKD. Comparative analysis of mortality and clinical outcomes was performed based on CKD strata.
RESULTS: We identified 8701 patients who were treated with EVAR (n = 5811) or OAR (n = 2890) of intact AAAs. Mild, moderate, and severe CKD was present in 63%, 30%, and 7%, respectively. CKD increased (P < .01) overall mortality, with rates of 1.7% (mild), 5.3% (moderate), and 7.7% (severe) in unmatched patients undergoing EVAR or OAR. Operative mortality rates in patients with severe CKD were as high as 6.2% for EVAR and 10.3% for OAR. Severity of CKD was associated with increasing frequency of risk factors; therefore, propensity matching to control for comorbidities was performed, resulting in similar baseline clinical and demographic features of patients with mild compared with those with moderate or severe disease. In propensity-matched cohorts, moderate CKD increased the risk of 30-day mortality for EVAR (1.9% mild vs 3.2% moderate; P = .013) and OAR (3.1% mild vs 8.4% moderate; P < .0001). Moderate CKD was also associated with increased morbidity in patients treated with EVAR (8.3% mild vs 12.8% moderate; P < .0001) or OAR (25.2% mild vs 32.4% moderate; P = .001). Similarly, severe CKD increased the risk of 30-day mortality for EVAR (2.6% mild vs 5.7% severe; P = .0081) and OAR (4.1% mild vs 9.9% severe; P = .0057). Severe CKD was also associated with increased morbidity in patients treated with EVAR (10.6% mild vs 19.2% severe; P < .0001) or OAR (31.1% mild vs 39.6% severe; P = .04).
CONCLUSIONS: The presence of moderate or severe CKD in patients considered for AAA repair is associated with significantly increased mortality and therefore should figure prominently in clinical decision making. The high mortality of AAA repair in patients with severe CKD is such that elective repair in such patients is not advised, except in extenuating clinical circumstances.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22857808     DOI: 10.1016/j.jvs.2012.04.037

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  12 in total

1.  Clinical significance of type I endoleak on completion angiography.

Authors:  Suh Min Kim; Hwan Do Ra; Sang-Il Min; Hwan Jun Jae; Jongwon Ha; Seung-Kee Min
Journal:  Ann Surg Treat Res       Date:  2014-01-22       Impact factor: 1.859

Review 2.  Osteoprotegerin and kidney disease.

Authors:  Alejandra Montañez-Barragán; Isaias Gómez-Barrera; Maria D Sanchez-Niño; Alvaro C Ucero; Liliana González-Espinoza; Alberto Ortiz
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

3.  Variation in center-level frailty burden and the impact of frailty on long-term survival in patients undergoing elective repair for abdominal aortic aneurysms.

Authors:  Elizabeth L George; Rui Chen; Amber W Trickey; Benjamin S Brooke; Larry Kraiss; Matthew W Mell; Philip P Goodney; Jason Johanning; Jason Hockenberry; Shipra Arya
Journal:  J Vasc Surg       Date:  2019-05-27       Impact factor: 4.268

4.  Management of Immediate Post-Endovascular Aortic Aneurysm Repair Type Ia Endoleaks and Late Outcomes.

Authors:  Ali F AbuRahma; Stephen M Hass; Zachary T AbuRahma; Michael Yacoub; Albeir Y Mousa; Shadi Abu-Halimah; L Scott Dean; Patrick A Stone
Journal:  J Am Coll Surg       Date:  2016-12-23       Impact factor: 6.113

5.  Contrast Free Duplex-Assisted EVAR in Patients with Chronic Renal Insufficiency.

Authors:  Attila G Krasznai; Tim A Sigterman; Lee H Bouwman
Journal:  Ann Vasc Dis       Date:  2014-12-25

6.  Concurrent renal artery stent during endovascular infrarenal aortic aneurysm repair confers higher risk for 30-day acute renal failure.

Authors:  Besma Nejim; Isibor Arhuidese; Muhammmad Rizwan; Lana Khalil; Satinderjit Locham; Devin Zarkowsky; Philip Goodney; Mahmoud B Malas
Journal:  J Vasc Surg       Date:  2017-02-17       Impact factor: 4.268

7.  Postoperative renal dysfunction independently predicts late mortality in patients undergoing aortic reconstruction.

Authors:  Virendra I Patel; Robert T Lancaster; Emel Ergul; Mark F Conrad; Daniel Bertges; Marc Schermerhorn; Philip Goodney; Richard P Cambria
Journal:  J Vasc Surg       Date:  2015-12       Impact factor: 4.268

8.  The impact of concomitant procedures during endovascular abdominal aortic aneurysm repair on perioperative outcomes.

Authors:  Klaas H J Ultee; Sara L Zettervall; Peter A Soden; Jeremy Darling; Jeffrey J Siracuse; Matthew J Alef; Hence J M Verhagen; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2016-03-16       Impact factor: 4.268

9.  A perioperative strategy for abdominal aortic aneurysm in patients with chronic renal insufficiency.

Authors:  Makoto Haga; Katsuyuki Hoshina; Kunihiro Shigematsu; Toshiaki Watanabe
Journal:  Surg Today       Date:  2015-12-08       Impact factor: 2.549

10.  Late outcomes of endovascular aortic stent graft therapy in patients with chronic kidney disease.

Authors:  Chung-Cheng Wu; An-Hsun Chou; Yu-Sheng Lin; Victor Chien-Chia Wu; Shang-Hung Chang; Pao-Hsien Chu; Yu-Ting Cheng; Po-Jen Ko; Kuo-Sheng Liu; Shao-Wei Chen
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.